Bluesky Facebook Reddit Email

Active monitoring with or without endocrine therapy for low-risk ductal carcinoma in situ

12.12.24 | JAMA Network

SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

About The Study: Women with low-risk ductal carcinoma in situ randomized to active monitoring did not have a higher rate of invasive cancer in the same breast at 2 years compared with those randomized to guideline-concordant care.

Corresponding Author: To contact the corresponding author, E. Shelley Hwang, MD, MPH, email shelley.hwang@duke.edu .

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2024.26698)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Media advisory: This study is being presented at the San Antonio Breast Cancer Symposium.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.26698?guestAccessKey=e1ebba48-d10d-4114-8084-88cdc40c929c&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=121224

JAMA

Keywords

Article Information

Contact Information

JAMA Network Media Relations
JAMA Network
mediarelations@jamanetwork.org

How to Cite This Article

APA:
JAMA Network. (2024, December 12). Active monitoring with or without endocrine therapy for low-risk ductal carcinoma in situ. Brightsurf News. https://www.brightsurf.com/news/80E234E8/active-monitoring-with-or-without-endocrine-therapy-for-low-risk-ductal-carcinoma-in-situ.html
MLA:
"Active monitoring with or without endocrine therapy for low-risk ductal carcinoma in situ." Brightsurf News, Dec. 12 2024, https://www.brightsurf.com/news/80E234E8/active-monitoring-with-or-without-endocrine-therapy-for-low-risk-ductal-carcinoma-in-situ.html.